Ovarian-cancer-targeted polypeptide

Abstract

The invention discloses an ovarian-cancer-targeted polypeptide. The polypeptide is screened from a tumor model of ovarian cancer by using phage display peptide library technology and the amino acid sequence of the polypeptide is WSGPGVWGASUK. Identification proves that the polypeptide can distinguish ovarian cancer cells from normal cells and ovarian cancer cells from other cancer cells, and thus can be combined with ovarian cancer cells specifically and be effectively internalized by the ovarian cancer cells. Serving as a medicine carrier, the polypeptide can improve the absorption of medicines. After being injected into the tumor model through vines, the polypeptide can be enriched in the tumor area of the ovarian cancer. The polypeptide is a totally new polypeptide with invivo targeting capacity proved, and the polypeptide can be used as an ideal ligand to construct a targeting carrier for transmitting anticancer medicines.

Description

technical field [0001] The invention belongs to the technical field of protein and polypeptides, and relates to a polypeptide with ovarian cancer-targeting properties screened in an ovarian cancer tumor model in vivo by using phage display peptide library technology, including the amino acid sequence of the polypeptide and the corresponding nucleotide sequence. Background technique [0002] Ovarian cancer is a common gynecological tumor. Its incidence rate ranks third after breast cancer and uterine body cancer. It is highly malignant and its lethality is second only to breast cancer. It seriously threatens women's lives. Statistics show that around 225,500 women worldwide were diagnosed with ovarian cancer in 2011 and 140,200 women died from the disease. For a long time, great advances in resection, radiotherapy and chemotherapy have not improved the survival rate of ovarian cancer patients, so it is urgent to develop more new technologies to solve this problem. Among them...

AI Technical Summary

Problems solved by technology

Up to now, this technology has successfully screened targeting peptides for liver cancer, prostate cancer, breast cancer and other human tumors, but there are few reports on screening ovarian cancer targeting ligands

At present, only the groups of Renata Pasqualini and Wadih Arap have applied this technology to in vitro screening of patient ascites (Oncogene, 2004 (23): 8859-8867) and ovarian cancer cells (Cancer Res, 2006 (1): 34-40) to obtain targetable drugs. However, the above researches all focus on in vitro cell or protein research, and have not evaluated the in vivo targeting properties of the peptide and the ability to use it as a ligand for drug delivery.

Images